Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

20.450
-0.570-2.71%
Volume:597.87K
Turnover:12.24M
Market Cap:2.59B
PE:131.16
High:20.920
Open:20.790
Low:20.150
Close:21.020
52wk High:23.760
52wk Low:11.000
Shares:126.64M
Float Shares:108.39M
Volume Ratio:0.95
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.156
EPS(LYR):0.233
ROE:6.17%
ROA:2.58%
PB:7.77
PE(LYR):87.88

Loading ...

Company Profile

Company Name:
NEUREN PHARMACEUTICALS LTD
Exchange:
ASX
Establishment Date:
2001
Employees:
8
Office Location:
117 Camberwell Road,Suite 1.01,Hawthorn East,Victoria,Australia
Zip Code:
3123
Fax:
- -
Introduction:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.